Drugs / Gocatamig
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07227597 | Jan 2026 → Nov 2030 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06780137 | Feb 2025 → Apr 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04471727 | Dec 2020 → Jan 2028 expected | small cell lung carcinoma | Harpoon Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gocatamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04471727 ↗ |
| Action | Deplete | “uses a person's immune system to find and destroy cancer cells” NCT06780137 ↗ |
| Modality | Other / unclassified | “Gocatamig is a T-cell engager therapy.” NCT07227597 ↗ |
| Route | Intravenous | “IV infusion” NCT04471727 ↗ |